NC 100150. (Clariscan, PEG-Ferron).
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D003287:Contrast Media / Q000493:pharmacokinetics; D003911:Dextrans; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics; D052203:Ferrosoferric Oxide; D006801:Humans; D007501:Iron / Q000008:administration & dosage / Q000493:pharmacokinetics; D018810:Magnetic Resonance Angiography / Q000379:methods*; D058185:Magnetite Nanoparticles; D008325:Mammary Neoplasms, Experimental / Q000473:pathology; D008863:Microspheres; D010087:Oxides / Q000008:administration & dosage / Q000493:pharmacokinetics; D013552:Swine
D003287:Contrast Media; D003911:Dextrans; D005290:Ferric Compounds; D058185:Magnetite Nanoparticles; D010087:Oxides; C097921:ferumoxtran-10; C000499:ferric oxide; D007501:Iron; D052203:Ferrosoferric Oxide